期刊文献+

B3(ds-scFv)靶向超抗原的制备及活性鉴定 被引量:1

Preparation and Evaluation of B3(ds-scFv) Targeted SEA
下载PDF
导出
摘要 To construct the expression vector of a recombinant toxin composed of a disulfide stable single-chain antibody from mAbB3 and SEA(D227A),the binding ability and cytotoxicity of the purified renatured products against the B3 positive carcinoma cells was examined. The VH and VL fragments of the mAbB3 were ligated by overlap PCR, the PCR product was cloned to the pET22b expression vector, then the SEA fragment was inserted into the B3dsscFv-pET22b expression vector which was digested by the same restriction enzymes. The expression plasmid was identified by restriction endonucleases digestion and transformed into E.coli BL21(DE3) followed by IPTG induction. The inclusion body was purified through SP-Sepharose cation exchange column after denaturing and refolding and the binding and cytotoxic ability of the purified products was examined by cell-ELISA and non-radioactive cell proliferation assay seperately. The expression vector B3dsscFv-SEA-pET was constructed successfully and the expression product exists mainly in the inclusion body, amounting to 33% of the total protein. The refolding product remains the binding ability of the single-chain antibody and has cytotoxic effect on HT-29 colon carcinoma cells. The stability assay showed that the resulting protein was stable at 37℃. This genetically engineered B3dsscFv-SEA fusion protein has bifunction of tumor targeting and tumor cell killing and promises to be an effective reagent for tumor targeted immunotherapy. To construct the expression vector of a recombinant toxin composed of a disulfide stable single-chain antibody from mAbB3 and SEA( D227A), the binding ability and cytotoxicity of the purified renatured products against the B3 positive carcinoma cells was examined. The VH and VL fragments of the mAbB3 were ligated by overlap PCR, the PCR product was cloned to the pET22b expression vector, then the SEA fragment was inserted into the B3 dsscFv-pET22b expression vector which was digested by the same restriction enzymes. The expression plasmid was identified by restriction endonucleases digestion and transformed into E.coli BL21 (DE3) followed by IPTG induction. The inclusion body was purified through SP-Sepharose cation exchange column after denaturing and refolding and the binding and cytotoxic ability of the purified products was examined by cell-ELISA and non-radioactive cell proliferation assay seperately. The expression vector B3dsscFv-SEA-pET was constructed successfully and the expression product exists mainly in the inclusion body, amounting to 33% of the total protein. The refolding product remains the binding ability of the singlechain antibody and has cytotoxic effect on HT-29 colon carcinoma cells. The stability assay showed that the resulting protein was stable at 37℃. This genetically engineered B3dsscFv-SEA fusion protein has bifunction of tumor targeting and tumor cell killing and promises to be an effective reagent for tumor targeted immunotherapy.
出处 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2005年第4期565-570,共6页 Chinese Journal of Biochemistry and Molecular Biology
基金 国家自然科学基金资助项目(No.30171091 No.30271478) 北京市自然科学基金资助项目(No.7022031)~~
关键词 活性鉴定 超抗原 主要组织相容性复合体 金黄色葡萄球菌 细胞毒性T淋巴细胞 制备 T细胞 加工处理 抗原递呈 B3 monoclonal antibody, disulfide stable single-chain antibody, SEA, tumor targeting
  • 相关文献

参考文献14

  • 1Kalland T, Dohlsten M, Abrahmsen L, Hedlund G, Bjork P, Lando P A, Sundstedt A, Akerblom E, Lind P. Targeting of superantigens. Cell Biophys, 1993,22(1-3): 147 ~ 164.
  • 2Hansson J, Ohlsson L, Persson R, Andersson G, Ilback N G, Litton M J, Kalland T, Dohlsten M. Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci USA, 1997,94(6) :2489~ 2494.
  • 3Dohlsten M., Hedlmd G. , Akerblom E., Lando P A. , Kalland T.antibody-targeted superantigens: a different class of anti-tumor agents.Proc Natl Acad Sci USA ,1991 ,88 (20): 9287 ~ 9291.
  • 4Brinkmann U, Pai L H, FitzGerald D J, Willingham M, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA,1991 ,88(19) :8616 ~ 8620.
  • 5Pai L H, Batra J K, FitzGerald D J, Willingham M C, Pastan I.Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.Cancer Res, 1992,52( 11 ): 3189 ~ 3193.
  • 6Rajagopal V, Pastan I, Kreitman R J. A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its singlechain and disulfide-stabilized homologs. Protein Eng, 1997,10(12):1453~ 1459.
  • 7Reiter Y, Brinkmann U, Jung S H, Lee B, Kasprzyk P G, King C R,Pastan I. Improved binding and antitumor activity of a recombinant antierbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem, 1994,269(28): 18327 ~ 18331.
  • 8Bera T K, Onda M, Brinkmann U, Pastan I. A bivalent disulfidestabilized Fv with improved antigen binding to erbB2. J Mol Biol,1998,281(3) :475 ~ 483.
  • 9Jung S H, Pastan I, Lee B. Design of interchain disulfide bonds in the framework region of the Fy fragment of the monoclonal antibody B3.Proteins, 1994,19( 1 ): 35 ~ 47.
  • 10Brinkmann U, Reiter Y, Jung S H, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Nail Acad Sci USA, 1993,90(16) :7538 ~ 7542.

二级参考文献2

同被引文献17

  • 1顾锦法,刘新垣.癌症的靶向基因—病毒治疗[J].自然杂志,2005,27(2):85-89. 被引量:6
  • 2司少艳,隋延仿,张秀敏,李侠,冯凯,韩瑞刚.肝癌靶向性SEA基因重组腺病毒载体的构建及体外生物学活性鉴定[J].中国肿瘤,2007,16(7):536-540. 被引量:2
  • 3Hopkins PA, Fraser JD, Pridmore AC, et al. Superantigen recognition by HLA class Ⅱ on monocytes up -regulates toll -like receptor 4 and enhances proinflammatory responses to endotoxin [ J ]. Blood, 2005,105 ( 9 ) : 3655 - 3662.
  • 4Ardern-Jones MR, Black AP, Bateman EA, et al. Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells [J]. Proc Natl Acad Sci USA, 2007,104( 13 ):5557 - 5562.
  • 5Cauley LS, Miller EE, Yen M, et al. Superantigen - induced CD4 T cell tolerance mediated by myeloid cells and IFN -γ [ J ]. J Immunol,2000,165 ( 11 ) :6056 - 6066.
  • 6Stohl W, Xu D, Zang S, et al. In vivo staphylococcal superantigen - driven polyclonal Ig responses in mice: dependence upon CD4^+ cells and human MHC class Ⅱ [J]. Int Immunol,2001,13 (10) :1291 - 1300.
  • 7Suzuki H, Hayakawa A, Bouchard D, et al. Normal thymic selection, superantigen - induced deletion and Fas - mediated apoptosis of T cells in IL -2 receptor β chain -deficient mice [J]. Int Immunol,1997,9(9) :1367 - 1374.
  • 8Dauwalder O, Thomas D, Ferry T, et al. Comparative inflammatory properties of staphylococcal superantigenic enterotoxins SEA and SEG: implications for septic shock [J]. J Leukoc Biol,2006,80 (10) :753 -758.
  • 9Dohlsten M, Abrahmsen L, Bjork P, et al. Monoclonal antibody - superantigen fusion proteins : Tumor - specific agents for T - cell - based tumor therapy [ J ]. Proc Natl Acad Sci USA, 1994,91 ( 19 ) :8945 - 8949.
  • 10Wahlsten JL, Mills CD, Ramakrishnan S. Antitumor response elicited by a superantigen - transmembrane sequence fusion protein anchored onto tumor cells [ J ]. J Immunol, 1998,161 ( 12 ) :6761 - 6767.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部